Acer Therapeutics
Newton
About Acer Therapeutics
Acer Therapeutics is a pharmaceutical company that focuses on the acquisition, development, and commercialization of therapies for serious, rare, and life-threatening diseases with unmet medical needs. Its pipeline includes four clinical-stage candidates: emetine hydrochloride for the treatment of patients with COVID-19; ACER-001 (a taste-masked, immediate-release formulation of sodium phenylbutyrate), for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO (celiprolol), for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and osanetant, for the treatment of induced Vasomotor Symptoms (iVMS). The company was founded in 2013 and is headquartered in Newton, Massachusetts.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $116.9M
- Funding stage: M&A
- Last round: Post-IPO Debt (Jun 2023)
- Ticker: nasdaq:ACER
- Website: acertx.com
- Phone: (844) 902-6100
Industries & Categories
Biotechnology, Medical, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/acer-therapeutics-164146 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.